REGENXBIO Receives FDA Fast Track Designation for its Novel Gene Therapy Candidate
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.
Penn and PCI recognized in the Daily Pennsylvanian for licensing income and spinout companies
Penn was highlighted in The Daily Pennsylvanian for ranking first in annual licensing income among 153 research institutions.
Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Penn I-Corps Launches Spring 2023 cohort
The cohort started at the end of February and is underway. Teams are currently engaged in reaching out and conducting Customer discovery interviews.
PCI Featured as the Philadelphia Business Journal Cover Story
This in-depth interview with Swartley provides a comprehensive history about technology transfer at Penn as well as the establishment and current success of PCI.
Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Penn Ranks First in Licensing Income
Penn officially ranked number one in terms of licensing income in the latest Association of University Technology Managers (AUTM) annual survey, which included 153 reporting institutions.
PCI Activities Highlighted by the CEO Council for Growth
The CEO Council for Growth recently highlighted PCI's annual review and JP Morgan Conference event in its newsletter.
PACT Enterprise Awards
PCI supported Penn spinouts Interius BioTherapeutics, Verismo Therapeutics, viTToria biotherapeutics, Exyn Technologies, and Avisi Technologies are all nominated for awards.